Lotilibcin

Summary

Lotilibcin (WAP‑8294A2) is a cyclic lipodepsipeptide antibiotic of the polymyxin family that is being investigated for the treatment of infections caused by methicillin‑resistant Staphylococcus aureus (MRSA). It is administered intravenously and has shown potent in‑vitro activity (MIC 0.2–0.8 µg/mL) and superior in‑vivo efficacy compared with vancomycin in pre‑clinical models.

Mechanism of Action

Evidence from synthetic studies indicates that Lotilibcin exerts its antibacterial effect by disrupting the bacterial cell membrane. This membrane‑lytic activity is dependent on the presence of menaquinone, an essential component of the bacterial respiratory chain, suggesting that the compound targets menaquinone‑associated membrane functions to cause rapid lysis of Gram‑positive cells.

What the Research Shows

Two recent studies illuminate Lotilibcin's potential. An ACS Synthetic Biology report described a CRISPR/dCas9‑based strategy that increased production of WAP‑8294A compounds in Lysobacter, raising yields of Lotilibcin up to four‑fold and confirming its potent activity against a panel of Gram‑positive pathogens (MIC 0.2‑0.8 µg/mL). A Journal of Organic Chemistry paper reported the first total synthesis of Lotilibcin and a deoxy analogue, demonstrating that both are equipotent against MRSA and that their antibacterial action involves menaquinone‑dependent membrane disruption. The same study noted superior in‑vivo efficacy to vancomycin in animal models, while the yield‑improvement work highlighted the challenges of natural production.

Reported Benefits

Lotilibcin shows very low MIC values against MRSA and other Gram‑positive bacteria, indicating strong potency. In animal infection models it outperformed vancomycin, suggesting potential clinical advantage. Its distinct mechanism—membrane disruption linked to menaquinone—differs from many existing antibiotics, which may reduce cross‑resistance. The recent synthetic route enables laboratory access for further investigation.

Limitations of the Evidence

Lotilibcin remains investigational; clinical trial results are not reported in the available literature. Production from the native Lysobacter strain is low, requiring genetic engineering for scale‑up. The exact molecular target beyond menaquinone‑dependent membrane effects is not fully defined, and efficacy data are limited to in‑vitro assays and animal models. No human safety or pharmacokinetic data are provided.

Safety Considerations

No adverse‑event or toxicity information is presented in the cited abstracts. As an investigational intravenous agent, Lotilibcin's safety profile in humans is currently unknown, and caution is warranted pending formal clinical evaluation. Potential risks associated with membrane‑active antibiotics, such as off‑target cell toxicity, cannot be ruled out without further data.

How It Is Administered

Lotilibcin is formulated for intravenous administration. Specific dosage forms, concentrations, or infusion protocols have not been disclosed in the literature.

Routes of Administration

Goals & Uses

• Treatment of serious Gram-positive infectionsAntibacterial / Infectious DiseaseModerate
• Treatment of MRSA bacteremiaAntibacterial / Infectious DiseaseModerate
• Treatment of vancomycin-resistant Enterococcus (VRE) infectionsAntibacterial / Infectious DiseaseLow
• Alternative to vancomycin for resistant organismsAntibacterial / Infectious DiseaseLow

Contraindications

• Severe pre-existing renal impairmentRenalModerate
• Known hypersensitivity to lotilibcin or related lipodepsipeptidesAllergyHigh

Adverse Effects

• NeurotoxicityNeurologicalRare
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
• NephrotoxicityRenalUncommon
• Infusion-site reactionsLocal / AdministrationCommon

Drug Interactions

• AminoglycosidesModerate
• VancomycinModerate
• NSAIDsLowMay increase renal risk in susceptible patients

Population Constraints

• Pediatric patientsAgeRelative
• Patients with renal impairmentOrgan ImpairmentRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalNot EMA approved; no marketing authorization granted.
• United StatesInvestigationalNot FDA approved; investigational use only.
• United KingdomInvestigationalNot approved by MHRA; investigational status.

Investigational drug; has received limited regulatory designations. Phase I/II clinical trials have been conducted primarily in Asia. Not approved in any jurisdiction as of knowledge cutoff.

Evidence & Sources

• Yield Improvement of the Anti-MRSA Antibiotics WAP-8294A by CRISPR/dCas9 Combined with Refactoring Self-Protection Genes in Lysobacter enzymogenes OH11
  Journal ArticleLowYu L, et al.2018-01-01T00:00:00.000000Z
• Total Synthesis and Biological Mode of Action of WAP-8294A2: A Menaquinone-Targeting Antibiotic
  Journal ArticleLowItoh H, et al.2018-01-01T00:00:00.000000Z

Frequently Asked Questions